KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.

Abolghasem Allahyari, Ali Ehsanpour, Behrouz Najafi, Nafseh Ansarinejad, Valiollah Mehrzad, Behjat Kalantari, Jahangir Raafat, Mojtaba Ghadiany, Farhad Shahi, Behrooz Gharib, Vahid Moazed, Adnan Khosravi, Mir Hossein Mirpour, Sina Salari, Seyedmohammadreza Mortazavizadeh, Amirabbas Nekoyi, Mohsen Khani, Alireza Sadeghi, Sirus Gharib, Alireza Bary, Mehrzad Mirzania, Shirin Haghighat, Seyed Mohsen Razavi, Seyed Amir Hossein Emami, Mehran Hosseinzadeh, Mahdi Mirbolouk, Sanambar Sadighi, Abdolali Shahrasbi, Ali Esfahani, Masoumeh Gity, Nassim Anjidani, Hamidreza Kaf, Safa Najaf

BMC Cancer 22(1) 1348

PMID36550442
PMCIDPMC9784059
DOI10.1186/s12885-022-10455-0
发表日期2022-12-22
摘要

摘要

无摘要

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。